Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth-Reference-Cited by-同舟云学术

Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth

Published:2012-10-23 Issue:22 Volume:55 Page:9891-9899
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Bergman Joel A.¹,Woan Karrune²,Perez-Villarroel Patricio²,Villagra Alejandro²,Sotomayor Eduardo M.²,Kozikowski Alan P.¹

Affiliation:

1. Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, Chicago, Illinois 60612, United States

2. Department of Immunology and Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida 33613, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm301098e

Reference19 articles.

1. Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop Normally

2. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

3. Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis

4. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors

5. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy

Cited by 164 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small molecules targeting HDAC6 for cancer treatment: Current progress and novel strategies;Biomedicine & Pharmacotherapy;2024-09

2. Phase separation of phospho-HDAC6 drives aberrant chromatin architecture in triple-negative breast cancer;Nature Cancer;2024-08-28

3. Selective HDAC6 Inhibition Has the Potential for Anti-Cancer Effect in Renal Cell Carcinoma;Journal of Personalized Medicine;2024-06-30

4. In-Cell Testing of Zinc-Dependent Histone Deacetylase Inhibitors in the Presence of Class-Selective Fluorogenic Substrates: Potential and Limitations of the Method;Biomedicines;2024-05-29

5. First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer’s Disease;ACS Chemical Neuroscience;2024-05-15